Details of the Drug Reposition

General Information of This Drug (ID: DMMQ2OW)

Drug Name
Nintedanib   DMMQ2OW
Synonyms Nintedanib; Vargatef; 656247-17-5; BIBF-1120; Intedanib; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; G6HRD2P839; 1160294-26-7; CHEBI:85164; Nintedanib
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian neoplasm DISEAFTY N.A. Approved [1]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Approved [1]
Idiopathic pulmonary fibrosis DISZGA69 CB03.4 Approved [2]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Nintedanib FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
3 ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.